Brian Kemp Dolliver
Analyst
Brookline Capital Markets
Equibles does not estimate personal net worth.
About Brian Kemp Dolliver
Brian Kemp Dolliver is recorded as Analyst at Brookline Capital Markets. Brian Kemp Dolliver has spoken on 2 earnings calls and 2 other investor events across 3 companies, most recently for Outlook Therapeutics, Inc. on August 14, 2026. Those appearances were for Outlook Therapeutics, Inc. (OTLK), Candel Therapeutics, Inc. (CADL) and Dare Bioscience, Inc. (DARE). The companies whose calls Brian Kemp Dolliver spoke on are classified in the Healthcare sector.
Brian Kemp Dolliver on recent calls
“I think our goal is to get into the market, demonstrate what the quality and the reimbursement and the experiences with us and then and grow from there and then obviously expand that as we get the permanent j code super thanks i'll get back in the queue thank you thank you the next question comes from douglas sal with…”
“So, it sounds like you're assuming that patients who are in traditional Medicare will use compounded product because it's dirt cheap. and so any upside related to that is going to be in that population.”
“My first question for the experts is, considering the asset's potential mode of administration, could you provide some color on how this potential could be viewed as invasive, differs from the prostatectomy procedure?”
“First, with regard to the Ovaprene trial and the interplay between enrollment phase and cycles. Sabrina, what kind of impact could this have on the timing of the readout?”
Affiliation history
-
Brookline Capital Markets
Analyst
Source not stated
Current
Company network
Recent activity
-
-
-
Annual General Meeting AUA Annual Meeting - Candel Therapeutics Call Candel Therapeutics, Inc. (CADL)
-